Phase II testing of sunitinib: the National Cancer Institute of Canada Clinical Trials Group IND Program Trials IND.182-185.
Sunitinib (SU11248) is an orally bioavailable inhibitor that affects the receptor tyrosine kinases involved in tumour proliferation and angiogenesis, including vascular endothelial growth factor (VEGF) receptors 1, 2, 3, and platelet-derived growth factor receptors alpha (PDGFRA) and beta (PDGFRB). Because angiogenesis is necessary for the growth and metastasis of solid tumours, and VEGF is believed to have a pivotal role in that process, SUNITINIB treatment may have broad-spectrum clinical utility. In the present article, we discuss the biologic and clinical rationales that have recently led the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group to initiate four phase ii trials testing this agent in the following four different tumour types: relapsed diffuse large cell lymphoma, malignant pleural mesothelioma, locally advanced or metastatic cervical cancer and recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.
Buckstein
R
R
Division of Hematology, Odette Cancer Center, Toronto, Ontario.
Meyer
R M
RM
Seymour
L
L
Biagi
J
J
Mackay
H
H
Laurie
S
S
Eisenhauer
E
E
J Pharmacol Exp Ther. 2005 Dec;315(3):971-9
16002463
Lancet. 2006 Oct 14;368(9544):1329-38
17046465
Gynecol Oncol. 2002 Jun;85(3):469-75
12051876
Leuk Lymphoma. 2005 Sep;46(9):1345-51
16109613
Clin Exp Metastasis. 2004;21(2):107-18
15168728
J Natl Cancer Inst. 2002 Oct 2;94(19):1484-93
12359857
J Clin Oncol. 1991 Mar;9(3):389-93
1999708
Med Oncol. 2001;18(4):269-75
11918453
Br J Haematol. 1999 Aug;106(2):504-9
10460612
Ann Oncol. 2004 Feb;15(2):257-60
14760119
J Pathol. 2001 Apr;193(4):468-75
11276005
J Clin Oncol. 1996 Mar;14(3):792-5
8622025
Blood. 2001 Jun 1;97(11):3658-61
11369666
Science. 2006 Sep 22;313(5794):1785-7
16990548
Curr Opin Oncol. 2005 Nov;17(6):611-6
16224242
Clin Cancer Res. 2003 Jan;9(1):377-82
12538491
Am J Obstet Gynecol. 1993 Mar;168(3 Pt 1):805-7
8456884
J Clin Oncol. 1985 Aug;3(8):1079-85
3894589
Int J Oncol. 2000 Apr;16(4):777-82
10717248
Am J Epidemiol. 2004 Jan 15;159(2):107-12
14718210
Cancer Res. 2001 Jun 1;61(11):4341-4
11389057
Cancer Metastasis Rev. 2000;19(1-2):167-72
11191056
Ann Oncol. 2005;16 Suppl 8:viii13-viii19
16239232
Blood. 2005 Feb 1;105(3):986-93
15459012
Blood. 2004 Nov 1;104(9):2893-902
15238424
J Clin Oncol. 2005 Jul 20;23(21):4626-33
15911865
N Engl J Med. 1987 Jun 11;316(24):1493-8
3295541
Radiother Oncol. 1995 May;35(2):107-17
7569018
Lancet. 2003 Jun 21;361(9375):2099-106
12826431
Exp Hematol. 2000 Sep;28(9):993-1000
11008011
Bone Marrow Transplant. 2003 Oct;32(7):673-9
13130314
Br J Cancer. 1999 Sep;81(1):54-61
10487612
Gynecol Oncol. 2005 Mar;96(3):902-5
15721449
Eur J Cancer. 1997 Mar;33(3):500-2
9155539
Oncogene. 2005 Jan 13;24(3):489-501
15516973
Virchows Arch. 1999 Jul;435(1):8-12
10431840
N Engl J Med. 2007 Jan 11;356(2):115-24
17215529
J Clin Oncol. 2007 Nov 20;25(33):5165-71
18024863
Cancer Cell. 2005 Jan;7(1):101-11
15652753
Mol Pathol. 2002 Dec;55(6):348-59
12456770
CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30
15661684
Blood. 2000 Jul 1;96(1):282-7
10891463
Int J Cancer. 2003 May 1;104(5):603-10
12594815
Leuk Lymphoma. 2009 May;50(5):728-35
19373598
Semin Oncol. 1994 Feb;21(1):54-62
8310310
Adv Exp Med Biol. 2003;522:83-97
12674213
N Engl J Med. 1993 Apr 8;328(14):1002-6
7680764
Blood. 1992 Oct 15;80(8):2142-8
1356515
J Clin Oncol. 2007 Mar 1;25(7):884-96
17327610
Semin Oncol. 2002 Apr;29(2 Suppl 6):18-22
12040530
Cancer. 2005 Feb 15;103(4):724-30
15637689
Clin Cancer Res. 2006 Sep 1;12(17):5190-8
16951238
Gynecol Oncol. 2001 May;81(2):213-5
11354055
Nat Med. 2003 Jun;9(6):653-60
12778163
Br J Cancer. 1997;76(9):1221-7
9365173